Allergan Inactive 10-Q2003 Q1 Quarterly report

Filed: 7 May 03, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: absence, accrue, accrued, affirmed, alternative, andAlphagan, andAvage, andLumigan, andZymar, answer, approvedBotox, Arnold, asLumigan, Australian, AVO, aware, Banc, binding, bothAlphagan, botulinum, Brazil, British, calendar, Canadian, cancellation, capacity, caption, cataract, certainAlphagan, cervical, collect, compensation, consortium, conversion, coveringAlphagan, critical, delivery, demurrer, disclaim, dystonia, EITF, Elan, element, elimination, Emerging, employ, En, encounter, enterprise, European, examination, expansion, expedited, exposure, expressly, favor, FIN, finalized, flexibility, followingpro, footnote, foreclose, formula, France, fraud, free, Gary, greatest, grew, guarantor, guidance, half, Headquartered, heard, implied, improper, incentive, incidental, Indirect, inequitable, invited, Irena, issuance, Klein, laboratory, largest, leader, life, liquidity, located, Medavoy, media, Medicaid, mentioned, merger, met, Mike, milestone, misconduct, misrepresentation, modified, monitor, monthly, Multiple, negligence, negligent, Neural, neurological, newly, nonemployee, nonrestricted, ofAcular, ofTazorac, ofVistabel, open, ourAlphagan, overturn, page, perfunctory, Petition, placement, pound, preferBotox, premium, previously, productAvage, prominent, proportion, proposed, prosecution, rapidly, rebate, recently, redeemed, redemption, registered, Rehearing, Request, resolution, restrict, restricted, retire, routinely, satisfactory, satisfied, scope, settled, similarly, size, slight, small, statute, stay, stayed, staying, stop, strength, strict, study, subsidiary, surgery, symbol, Task, theAcular, Thesepro, toAlphagan, tort, type, unamortized, uncertainty, unknown, unsecured, unused, update, valuation, version, voluntarily, world, worth, York

Removed: Abbott, accelerate, accomplish, Alphagan, APB, assessment, assigning, authority, BSC, capitalized, carrying, classified, clinical, commencement, compare, component, compound, conform, Corporation, Corrupt, cumulative, customary, designate, detail, directly, disposed, Dutch, end, evaluated, exercisability, exist, expand, fallen, forma, formation, historically, illustrative, impaired, impairment, indefinite, Influenced, Infrequently, initiated, interpretive, Investigational, Justice, kind, licensing, Lumigan, obligated, occurred, Occurring, Organization, passed, permanent, Pharmacia, Phase, principle, Pro, Puerto, Racketeering, reference, refundable, reporting, requirement, resulted, rico, slightly, spinning, Swedish, Tazorac, test, transaction, unit, Unusual, wholly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Allergan similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 99.1

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Allergan, Inc., a Delaware corporation (the “Company”), hereby certifies, to such officer’s knowledge, that:

(i)		the accompanying Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 28, 2003 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii)		the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: May 6, 2003

		/s/ David E.I. Pyott

		David E.I. Pyott
		Chairman of the Board, President and Chief Executive Officer

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.